H.C. Wainwright initiated coverage on Upstream Bio with a new price target
Stocks in this Quantisnow insightHealth Care
Historical context for UPB
Across the 15 sessions after earlier UPB headlines, the stock closed higher 7 times and lower 8 times, with a median move of 4.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | UPB | SPY |
|---|---|---|---|
| Jun 3, 2026 | Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference | +5.2% | -0.7% |
| May 18, 2026 | Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference | -6.4% | -0.1% |
| May 13, 2026 | Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights | +4.6% | +0.6% |
| Apr 17, 2026 | Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference | -1.1% | +1.2% |
| Mar 27, 2026 | Upstream Bio downgraded by Evercore ISI with a new price target | -11.4% | -1.7% |
| Mar 26, 2026 | Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results | +3.4% | -1.8% |
Quantisnow market dataNASDAQ
UPB
Upstream Bio Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2024
Get push alerts for UPB
Full UPB profile on Quantisnow Follow UPB and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time